Liposomes encapsulating adenosine
US11607386B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2020 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | Apr 3, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.